Home
|
Inbox
|
Search
|
View Abstract
Relationship Between Peripheral Blood Myostatin Levels and Sarcopenia In COPD Patients
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A3128 - Relationship Between Peripheral Blood Myostatin Levels and Sarcopenia In COPD Patients
Author Block: S. Yoshida, K. Asai, A. Sugitani, K. Kojima, H. Kubo, Y. Kyomoto, T. Kawamoto, N. Maruyama, N. Ijiri, K. Yamada, T. Watanabe, Y. Tochino, K. Hirata; Graduate School of Medicine Osaka City University, Osaka, Japan.
[Introduction]Sarcopenia, loss of skeletal muscle mass and strength, is a one of the comorbidities of chronic obstructive pulmonary disease (COPD) patients, which may deteriorate the quality of life in COPD patients. Myostatin is a member of the transforming growth factor β superfamily and, is secreted by skeletal muscles as negative regulator of skeletal muscle growth. Its deletion or loss of function induces muscle overgrowth, whereas its overexpression or systemic administration causes muscle atrophy. This study was designed to evaluate serum myostatin levels of COPD patients with and without sarcopenia, and to examine relationships between myostatin and sarcopenia, body composition and pulmonary function parameters. [Methods] Thirty-nine stable male COPD patients were enrolled. Pulmonary function testing was performed and body composition was evaluated by the bioelectrical impedance analysis. Serum myostatin levels were measured by ELISA. Sarcopenia was defined by the Asian Working Group for Sarcopenia standard, with Skeletal Muscle Mass Index(SMI) less than 7 kg/m2 and grip strength less than 26 kg. [Results] Myostatin levels were positively correlated with Muscle Mass, Fat Free Mass, Fat Free Mass Index and SMI in COPD patients. Nine COPD patients were sarcopenia and thirty COPD patients were non-sarcopenia. Myostatin levels were lower expressed in COPD patients with sarcopenia compared to those without sarcopenia. On the other hand, myostatin levels were not significantly correlated with pulmonary function parameters, such as %FVC, %FEV1 and FEV1/FVC. [Conclusion] In this study, we showed that myostatin had positive correlations with muscle mass parameters and that serum myostatin levels in COPD patients with sarcopenia were significantly lower than in those without sarcopenia. Myostatin might be a differentiational biomarker for COPD patients with sarcopenia.
Author Block: S. Yoshida, K. Asai, A. Sugitani, K. Kojima, H. Kubo, Y. Kyomoto, T. Kawamoto, N. Maruyama, N. Ijiri, K. Yamada, T. Watanabe, Y. Tochino, K. Hirata; Graduate School of Medicine Osaka City University, Osaka, Japan.
[Introduction]Sarcopenia, loss of skeletal muscle mass and strength, is a one of the comorbidities of chronic obstructive pulmonary disease (COPD) patients, which may deteriorate the quality of life in COPD patients. Myostatin is a member of the transforming growth factor β superfamily and, is secreted by skeletal muscles as negative regulator of skeletal muscle growth. Its deletion or loss of function induces muscle overgrowth, whereas its overexpression or systemic administration causes muscle atrophy. This study was designed to evaluate serum myostatin levels of COPD patients with and without sarcopenia, and to examine relationships between myostatin and sarcopenia, body composition and pulmonary function parameters. [Methods] Thirty-nine stable male COPD patients were enrolled. Pulmonary function testing was performed and body composition was evaluated by the bioelectrical impedance analysis. Serum myostatin levels were measured by ELISA. Sarcopenia was defined by the Asian Working Group for Sarcopenia standard, with Skeletal Muscle Mass Index(SMI) less than 7 kg/m2 and grip strength less than 26 kg. [Results] Myostatin levels were positively correlated with Muscle Mass, Fat Free Mass, Fat Free Mass Index and SMI in COPD patients. Nine COPD patients were sarcopenia and thirty COPD patients were non-sarcopenia. Myostatin levels were lower expressed in COPD patients with sarcopenia compared to those without sarcopenia. On the other hand, myostatin levels were not significantly correlated with pulmonary function parameters, such as %FVC, %FEV1 and FEV1/FVC. [Conclusion] In this study, we showed that myostatin had positive correlations with muscle mass parameters and that serum myostatin levels in COPD patients with sarcopenia were significantly lower than in those without sarcopenia. Myostatin might be a differentiational biomarker for COPD patients with sarcopenia.
|
Home
|
Inbox
|
Search
|